WebSpero Therapeutics Working Capitalis quite stable at the moment as compared to the past year. The company's current value of Working Capitalis estimated at 2.28 Million. Spero … WebSPRO Spero Therapeutics Inc. Annual Income Statement - WSJ Spero Therapeutics Inc. SPRO (U.S.: Nasdaq) View All companies AT CLOSE 4:00 PM EST 03/07/23 $1.69 USD …
Spero Therapeutics to Present Data at the 33rd European …
WebApr 10, 2024 · Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of . Spero … WebApr 14, 2024 · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today … sixth season
SPERO THERAPEUTICS, INC. : Entry into a Material Definitive …
WebSep 30, 2024 · As of November 10, 2024, the registrant had 51,776,053shares of common stock, $0.001 par value per share, outstanding. Forward-Looking STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that … WebApr 6, 2024 · Spero Therapeutics, Inc. (NASDAQ: SPRO) Q4 2024 Earnings Call Transcript March 30, 2024 Operator: Good afternoon, and welcome to Spero Therapeutics Fourth … WebJun 30, 2024 · Item 1.01 Entry into a Material Definitive Agreement. On June 30, 2024, Spero Therapeutics, Inc. (the "Company") entered into a license agreement (the "License Agreement") with Pfizer Inc. ("Pfizer").. Pursuant to the License Agreement, the Company has granted Pfizer the rights to develop, manufacture, and commercialize the Company's … sushi pop wirt